Alginate biomaterial for the treatment of myocardial infarction: Progress, translational strategies, and clinical outlook. From ocean algae to patient bedside.

Advanced Drug Delivery Reviews

Volumn 96, Issue , 2016, Pages 54-76

  Ruvinov, Emil ^a   Cohen, Smadar ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Affinity binding; Alginate; Biomaterials; Clinical trials; Myocardial infarction; Regeneration; Scaffolds; Tissue engineering

Indexed keywords

ALGINATE; BIOCOMPATIBILITY; BIOLOGICAL MATERIALS; BIOMATERIALS; CARDIOLOGY; GELATION; MEDICAL APPLICATIONS; REPAIR; SCAFFOLDS; STEM CELLS; STIFFNESS MATRIX; TISSUE; TISSUE ENGINEERING; TISSUE REGENERATION;

ACUTE MYOCARDIAL INFARCTION; AFFINITY BINDING; BIOMEDICAL APPLICATIONS; CLINICAL TRIAL; EXTRACELLULAR MATRICES; MYOCARDIAL INFARCTION; REGENERATION; THERAPEUTIC POTENTIALS;

SCAFFOLDS (BIOLOGY);

ALGINIC ACID; BIOMATERIAL; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; HYDROGEL;

BIOCOMPATIBILITY; CARDIAC IMPLANT; CELL ENCAPSULATION; CONTROLLED DRUG RELEASE; EXTRACELLULAR MATRIX; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYDROGEL; INTRACARDIAC PATCH; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROCAPSULE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TISSUE ENGINEERING; TISSUE REGENERATION; TISSUE REPAIR; ANIMAL; BROWN ALGA; CHEMISTRY; CLINICAL TRIAL (TOPIC); CYTOLOGY; DRUG EFFECTS; HEART; MYOCARDIAL INFARCTION; PHYSIOLOGY; PROCEDURES; REGENERATION; STEM CELL; STEM CELL TRANSPLANTATION;

ALGINATES; ANIMALS; BIOCOMPATIBLE MATERIALS; CLINICAL TRIALS AS TOPIC; HEART; HUMANS; HYDROGELS; MYOCARDIAL INFARCTION; PHAEOPHYTA; REGENERATION; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE ENGINEERING;

EID: 84951775551     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.04.021     Document Type: Review

References (89)

1. Jessup M., Brozena S. Heart failure. N. Engl. J. Med. 2003, 348:2007-2018.
2. Ruvinov E., Sapir Y., Cohen S. Cardiac Tissue Engineering: Principles, Materials, and Applications 2012, Morgan & Claypool Publishers.
3. Ruvinov E., Dvir T., Leor J., Cohen S. Myocardial repair: from salvage to tissue reconstruction. Expert. Rev. Cardiovasc. Ther. 2008, 6:669-686.
4. Vunjak-Novakovic G., Lui K.O., Tandon N., Chien K.R. Bioengineering heart muscle: a paradigm for regenerative medicine. Annu. Rev. Biomed. Eng. 2011, 13:245-267.
5. Hirt M.N., Hansen A., Eschenhagen T. Cardiac tissue engineering: state of the art. Circ. Res. 2014, 114:354-367.
6. Ueno M., Oda T. Chapter six - biological activities of alginate. Advances in Food and Nutrition Research 2014, 95-112. Academic Press. K. Se-Kwon (Ed.).
7. Laurienzo P. Marine polysaccharides in pharmaceutical applications: an overview. Mar. Drugs 2010, 8:2435-2465.
8. Senni K., Pereira J., Gueniche F., Delbarre-Ladrat C., Sinquin C., Ratiskol J., Godeau G., Fischer A.M., Helley D., Colliec-Jouault S. Marine polysaccharides: a source of bioactive molecules for cell therapy and tissue engineering. Mar. Drugs 2011, 9:1664-1681.
9. Andersen T., Strand B.L., Formo K., Alsberg E., Christensen B.E. Chapter 9 alginates as biomaterials in tissue engineering. Carbohydrate Chemistry 2012, vol. 37:227-258. The Royal Society of Chemistry.
10. Gandhi J.K., Opara E.C., Brey E.M. Alginate-based strategies for therapeutic vascularization. Ther. Deliv. 2013, 4:327-341.
11. Al-Shamkhani A., Duncan R. Radioiodination of alginate via covalently-bound tyrosinamide allows monitoring of its fate in vivo. J. Bioact. Compat. Polym. 1995, 10:4-13.
12. Bouhadir K.H., Lee K.Y., Alsberg E., Damm K.L., Anderson K.W., Mooney D.J. Degradation of partially oxidized alginate and its potential application for tissue engineering. Biotechnol. Prog. 2001, 17:945-950.
13. Kong H.J., Kaigler D., Kim K., Mooney D.J. Controlling rigidity and degradation of alginate hydrogels via molecular weight distribution. Biomacromolecules 2004, 5:1720-1727.
14. Boontheekul T., Kong H.J., Mooney D.J. Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. Biomaterials 2005, 26:2455-2465.
15. Kong H.J., Alsberg E., Kaigler D., Lee K.Y., Mooney D.J. Controlling degradation of hydrogels via the size of crosslinked junctions. Adv. Mater. 2004, 16:1917-1921.
16. Lee K.Y., Mooney D.J. Alginate: properties and biomedical applications. Prog. Polym. Sci. 2012, 37:106-126.
17. Lee K., Silva E.A., Mooney D.J. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J. R. Soc. Interface 2011, 8:153-170.
18. https://clinicaltrials.gov.
19. Augst A.D., Kong H.J., Mooney D.J. Alginate hydrogels as biomaterials. Macromol. Biosci. 2006, 6:623-633.
20. Segers V.F., Lee R.T. Biomaterials to enhance stem cell function in the heart. Circ. Res. 2011, 109:910-922.
21. Templin C., Luscher T.F., Landmesser U. Cell-based cardiovascular repair and regeneration in acute myocardial infarction and chronic ischemic cardiomyopathy-current status and future developments. Int. J. Dev. Biol. 2011, 55:407-417.
22. Singelyn J.M., Christman K.L. Injectable materials for the treatment of myocardial infarction and heart failure: the promise of decellularized matrices. J. Cardiovasc. Transl. Res. 2010, 3:478-486.
23. Levit R.D., Landazuri N., Phelps E.A., Brown M.E., Garcia A.J., Davis M.E., Joseph G., Long R., Safley S.A., Suever J.D., Lyle A.N., Weber C.J., Taylor W.R. Cellular encapsulation enhances cardiac repair. J. Am. Heart Assoc. 2013, 2:e000367.
24. Roche E.T., Hastings C.L., Lewin S.A., Shvartsman D.E., Brudno Y., Vasilyev N.V., O'Brien F.J., Walsh C.J., Duffy G.P., Mooney D.J. Comparison of biomaterial delivery vehicles for improving acute retention of stem cells in the infarcted heart. Biomaterials 2014, 35:6850-6858.
25. Shapiro L., Cohen S. Novel alginate sponges for cell culture and transplantation. Biomaterials 1997, 18:583-590.
26. Zmora S., Glicklis R., Cohen S. Tailoring the pore architecture in 3-D alginate scaffolds by controlling the freezing regime during fabrication. Biomaterials 2002, 23:4087-4094.
27. Leor J., Aboulafia-Etzion S., Dar A., Shapiro L., Barbash I.M., Battler A., Granot Y., Cohen S. Bioengineered cardiac grafts. A new approach to repair the infarcted myocardium?. Circulation 2000, 102(Suppl. II):56-61.
28. Dar A., Shachar M., Leor J., Cohen S. Optimization of cardiac cell seeding and distribution in 3D porous alginate scaffolds. Biotechnol. Bioeng. 2002, 80:305-312.
29. Jones F.S., Jones P.L. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev. Dyn. 2000, 218:235-259.
30. Loeser R.F. Integrins and cell signaling in chondrocytes. Biorheology 2002, 39:119-124.
31. Makino H., Sugiyama H., Kashihara N. Apoptosis and extracellular matrix-cell interactions in kidney disease. Kidney Int. Suppl. 2000, 77:S67-S75.
32. Boudreau N.J., Jones P.L. Extracellular matrix and integrin signalling: the shape of things to come. Biochem. J. 1999, 339(Pt 3):481-488.
33. Lukashev M.E., Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 1998, 8:437-441.
34. Gumbiner B.M. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996, 84:345-357.
35. Shin H., Jo S., Mikos A.G. Biomimetic materials for tissue engineering. Biomaterials 2003, 24:4353-4364.
36. Rosso F., Giordano A., Barbarisi M., Barbarisi A. From cell-ECM interactions to tissue engineering. J. Cell. Physiol. 2004, 199:174-180.
37. Shachar M., Tsur-Gang O., Dvir T., Leor J., Cohen S. The effect of immobilized RGD peptide in alginate scaffolds on cardiac tissue engineering. Acta Biomater. 2011, 7:152-162.
38. Tsur-Gang O., Ruvinov E., Landa N., Holbova R., Feinberg M.S., Leor J., Cohen S. The effects of peptide-based modification of alginate on left ventricular remodeling and function after myocardial infarction. Biomaterials 2009, 30:189-195.
39. Sapir Y., Kryukov O., Cohen S. Integration of multiple cell-matrix interactions into alginate scaffolds for promoting cardiac tissue regeneration. Biomaterials 2011, 32:1838-1847.
40. Cardin A.D., Weintraub H.J. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 1989, 9:21-32.
41. Dvir T., Timko B.P., Brigham M.D., Naik S.R., Karajanagi S.S., Levy O., Jin H., Parker K.K., Langer R., Kohane D.S. Nanowired three-dimensional cardiac patches. Nat. Nanotechnol. 2011, 6:720-725.
42. Sapir Y., Polyak B., Cohen S. Cardiac tissue engineering in magnetically actuated scaffolds. Nanotechnology 2014, 25:014009.
43. Akhyari P., Kamiya H., Haverich A., Karck M., Lichtenberg A. Myocardial tissue engineering: the extracellular matrix. Eur. J. Cardiothorac. Surg. 2008, 34:229-241.
44. Dobaczewski M., Gonzalez-Quesada C., Frangogiannis N.G. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J. Mol. Cell. Cardiol. 2010, 48:504-511.
45. Braunwald E. Heart failure. JACC Heart Fail. 2013, 1:1-20.
46. Burdick J.A., Mauck R.L., Gorman J.H., Gorman R.C. Acellular biomaterials: an evolving alternative to cell-based therapies. Sci. Transl. Med. 2013, 5:176ps174.
47. Christman K.L., Lee R.J. Biomaterials for the treatment of myocardial infarction. J. Am. Coll. Cardiol. 2006, 48:907-913.
48. Rane A.A., Christman K.L. Biomaterials for the treatment of myocardial infarction a 5-year update. J. Am. Coll. Cardiol. 2011, 58:2615-2629.
49. Landa N., Miller L., Feinberg M.S., Holbova R., Shachar M., Freeman I., Cohen S., Leor J. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 2008, 117:1388-1396.
50. Leor J., Tuvia S., Guetta V., Manczur F., Castel D., Willenz U., Petnehazy O., Landa N., Feinberg M.S., Konen E., Goitein O., Tsur-Gang O., Shaul M., Klapper L., Cohen S. Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine. J. Am. Coll. Cardiol. 2009, 54:1014-1023.
51. Bellerophon BCM LLC IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction (PRESERVATION 1). Study NCT01226563 Available at:, (Accessed February 2, 2015). http://www.ClinicalTrials.gov.
52. BioLineRx Ltd Safety and Feasibility of the Injectable BL-1040 Implant. Study NCT00557531 Available at:, (Accessed February 2, 2015). http://www.ClinicalTrials.gov.
53. Sabbah H.N., Wang M., Gupta R.C., Rastogi S., Ilsar I., Sabbah M.S., Kohli S., Helgerson S., Lee R.J. Augmentation of left ventricular wall thickness with alginate hydrogel implants improves left ventricular function and prevents progressive remodeling in dogs with chronic heart failure. JACC Heart Fail. 2013, 1:252-258.
54. Yu J., Gu Y., Du K.T., Mihardja S., Sievers R.E., Lee R.J. The effect of injected RGD modified alginate on angiogenesis and left ventricular function in a chronic rat infarct model. Biomaterials 2009, 30:751-756.
55. Frey N., Linke A., Suselbeck T., Muller-Ehmsen J., Vermeersch P., Schoors D., Rosenberg M., Bea F., Tuvia S., Leor J. Intracoronary delivery of injectable bioabsorbable scaffold (IK-5001) to treat left ventricular remodeling after ST-elevation myocardial infarction: a first-in-man study. Circ. Cardiovasc. Interv. 2014, 7:806-812.
56. LoneStar Heart Inc. Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery. Study NCT00847964 Available at:, (Accessed February 2, 2015). http://www.ClinicalTrials.gov.
57. Lee R.J., Hinson A., Helgerson S., Bauernschmitt R., Sabbah H.N. Polymer-based restoration of left ventricular mechanics. Cell Transplant. 2012, 22:529-533.
58. Lee L.C., Wall S.T., Klepach D., Ge L., Zhang Z., Lee R.J., Hinson A., Gorman J.H., Gorman R.C., Guccione J.M. Algisyl-LVR with coronary artery bypass grafting reduces left ventricular wall stress and improves function in the failing human heart. Int. J. Cardiol. 2013, 168:2022-2028.
59. LoneStar Heart Inc. A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure (AUGMENT-HF). Study NCT01311791 Available at:, (Accessed February 2, 2015). http://www.ClinicalTrials.gov.
60. Wall S.T., Walker J.C., Healy K.E., Ratcliffe M.B., Guccione J.M. Theoretical impact of the injection of material into the myocardium: a finite element model simulation. Circulation 2006, 114:2627-2635.
61. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation 2003, 108:1395-1403.
62. Blackburn N.J., Sofrenovic T., Kuraitis D., Ahmadi A., McNeill B., Deng C., Rayner K.J., Zhong Z., Ruel M., Suuronen E.J. Timing underpins the benefits associated with injectable collagen biomaterial therapy for the treatment of myocardial infarction. Biomaterials 2015, 39:182-192.
63. Fisher S.A., Doree C., Mathur A., Martin-Rendon E. Meta-analysis of cell therapy trials for patients with heart failure - an update. Circ. Res. 2015, 116:1361-1377.
64. Menasche P. Stem cells in the management of advanced heart failure. Curr. Opin. Cardiol. 2014, 30:179-185.
65. Telukuntla K.S., Suncion V.Y., Schulman I.H., Hare J.M. The advancing field of cell-based therapy: insights and lessons from clinical trials. J. Am. Heart Assoc. 2013, 2:e000338.
66. Maltais S., Tremblay J.P., Perrault L.P., Ly H.Q. The paracrine effect: pivotal mechanism in cell-based cardiac repair. J. Cardiovasc. Transl. Res. 2010, 3:652-662.
67. Gnecchi M., Zhang Z., Ni A., Dzau V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 2008, 103:1204-1219.
68. Mirotsou M., Jayawardena T.M., Schmeckpeper J., Gnecchi M., Dzau V.J. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J. Mol. Cell. Cardiol. 2011, 50:280-289.
69. Ratajczak M.Z., Kucia M., Jadczyk T., Greco N.J., Wojakowski W., Tendera M., Ratajczak J. Pivotal role of paracrine effects in stem cell therapies in regenerative medicine: can we translate stem cell-secreted paracrine factors and microvesicles into better therapeutic strategies?. Leukemia 2012, 26:1166-1173.
70. Camussi G., Deregibus M.C., Cantaluppi V. Role of stem-cell-derived microvesicles in the paracrine action of stem cells. Biochem. Soc. Trans. 2013, 41:283-287.
71. Vandervelde S., van Luyn M.J., Tio R.A., Harmsen M.C. Signaling factors in stem cell-mediated repair of infarcted myocardium. J. Mol. Cell. Cardiol. 2005, 39:363-376.
72. Freeman I., Kedem A., Cohen S. The effect of sulfation of alginate hydrogels on the specific binding and controlled release of heparin-binding proteins. Biomaterials 2008, 29:3260-3268.
73. Freeman I., Cohen S. The influence of the sequential delivery of angiogenic factors from affinity-binding alginate scaffolds on vascularization. Biomaterials 2009, 30:2122-2131.
74. Shriver Z., Liu D., Sasisekharan R. Emerging views of heparan sulfate glycosaminoglycan structure/activity relationships modulating dynamic biological functions. Trends Cardiovasc. Med. 2002, 12:71-77.
75. Dvir T., Kedem A., Ruvinov E., Levy O., Freeman I., Landa N., Holbova R., Feinberg M.S., Dror S., Etzion Y., Leor J., Cohen S. Prevascularization of cardiac patch on the omentum improves its therapeutic outcome. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14990-14995.
76. Conti E., Carrozza C., Capoluongo E., Volpe M., Crea F., Zuppi C., Andreotti F. Insulin-like growth factor-1 as a vascular protective factor. Circulation 2004, 110:2260-2265.
77. Nakamura T., Mizuno S., Matsumoto K., Sawa Y., Matsuda H. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 2000, 106:1511-1519.
78. Hausenloy D.J., Yellon D.M. Cardioprotective growth factors. Cardiovasc. Res. 2009, 83:179-194.
79. Ruvinov E., Leor J., Cohen S. The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials 2011, 32:565-578.
80. Suleiman M.S., Singh R.J., Stewart C.E. Apoptosis and the cardiac action of insulin-like growth factor I. Pharmacol. Ther. 2007, 114:278-294.
81. Li Q., Li B., Wang X., Leri A., Jana K.P., Liu Y., Kajstura J., Baserga R., Anversa P. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J. Clin. Invest. 1997, 100:1991-1999.
82. Webster K.A. Programmed death as a therapeutic target to reduce myocardial infarction. Trends Pharmacol. Sci. 2007, 28:492-499.
83. Tomita N., Morishita R., Taniyama Y., Koike H., Aoki M., Shimizu H., Matsumoto K., Nakamura T., Kaneda Y., Ogihara T. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003, 107:1411-1417.
84. Nakamura T., Matsumoto K., Mizuno S., Sawa Y., Matsuda H. Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am. J. Physiol. 2005, 288:H2131-H2139.
85. Wang Y., Ahmad N., Wani M.A., Ashraf M. Hepatocyte growth factor prevents ventricular remodeling and dysfunction in mice via Akt pathway and angiogenesis. J. Mol. Cell. Cardiol. 2004, 37:1041-1052.
86. Frantz S., Bauersachs J., Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc. Res. 2009, 81:474-481.
87. Ruvinov E., Leor J., Cohen S. The effects of controlled HGF delivery from an affinity-binding alginate biomaterial on angiogenesis and blood perfusion in a hindlimb ischemia model. Biomaterials 2010, 31:4573-4582.
88. Hao X., Silva E.A., Mansson-Broberg A., Grinnemo K.H., Siddiqui A.J., Dellgren G., Wardell E., Brodin L.A., Mooney D.J., Sylven C. Angiogenic effects of sequential release of VEGF-A(165) and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc. Res. 2007, 75:178-185.
89. Banquet S., Gomez E., Nicol L., Edwards-Levy F., Henry J.P., Cao R., Schapman D., Dautreaux B., Lallemand F., Bauer F., Cao Y., Thuillez C., Mulder P., Richard V., Brakenhielm E. Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Circulation 2011, 124:1059-1069.